检索结果-南通市图书馆

World Journal of Clinical Cases 2024年第2期12卷 285-292页

作者： Sha-Sha Sun Xiao-Di Guo Wen-Dong Li Jing-Long Chen Department of Oncology Capital Medical University Affiliated Beijing Ditan HospitalBeijing 100015China

BACKGROUND Recently,combination therapy has shown a better trend towards improved tumour response and survival outcomes than monotherapy in patients with hepatocellular carcinoma(HCC).However,research on triple therapy[lenvatinib+sintilimab+transarterial chemoembolization(TACE)]as a first-line treatment for advanced HCC is limited.AIM To evaluate the safety and efficacy of triple therapy as a first-line treatment for advanced HCC.METHODS HCC patients with Barcelona Clinic Liver Cancer stage C treated with triple therapy were enrolled.All patients were treated with lenvatinib every day and sintilimab once every 3 wk.Moreover,TACE was performed every 4-6 wk if necessary.The primary outcome of the study was overall survival(OS).The secondary outcomes were the objective response rate(ORR),disease control rate(DCR),and incidence of adverse events.RESULTS Forty HCC patients who underwent triple therapy were retrospectively analysed from January 2019 to January 2022.With a median follow-up of 8.5 months,the 3-,6-,and 12-mo OS rates were 100%,88.5%,and 22.5%,respectively.The ORR and DCR were 45%and 90%,respectively.The median progressive free survival and median OS were not reached.Common complications were observed in 76%of the patients(grade 3,15%;grade 4,2.5%).CONCLUSION Combination therapy comprising lenvatinib,sintilimab and TACE achieved promising outcomes in advanced HCC patients and had manageable effects.

关键词： Lenvatinib Sintilimab advanced hepatocellular carcinoma Combination therapy Tumor response

Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2023年第3期10卷 403-414页

作者： Yi Lu Yue Gao Huan Yang Yong Hu Xin Li Department of Polymeric Materials School of Materials Science and EngineeringTongji UniversityShanghai 201804China Institute of Biotechnology RWTH Aachen University52074 AachenGermany DWI-Leibniz-Institute for Interactive Materials e.V. 52056 AachenGermany College of Chemistry Chemical Engineering and BiotechnologyDonghua UniversityShanghai 201620China School of Pharmacy Jiangsu UniversityZhenjiang 212013JiangsuChina Institute of Technical and Macromolecular Chemistry RWTH Aachen University52074 AachenGermany

Traditional treatments for advanced hepatocellular carcinoma(HCC),such as surgical resection,transplantation,radiofrequency ablation,and chemotherapy are unsatisfactory,and therefore the exploration of powerful therapeutic strategies is urgently needed.Immunotherapy has emerged as a promising strategy for advanced HCC treatment due to its minimal side effects and long-lasting therapeutic memory effects.Recent studies have demonstrated that icaritin could serve as an immunomodulator for effective immunotherapy of advanced HCC.Encouragingly,in 2022,icaritin soft capsules were approved by the National Medical Products Administration(NMPA)of China for the immunotherapy of advanced HCC.However,the therapeutic efficacy of icaritin in clinical practice is impaired by its poor bioavailability and unfavorable in vivo delivery efficiency.Recently,functionalized drug delivery systems including stimuli-responsive nanocarriers,cell membrane-coated nanocarriers,and living cell-nanocarrier systems have been designed to overcome the shortcomings of drugs,including the low bioavailability and limited delivery efficiency as well as side effects.Taken together,the development of icaritin-based nanomedicines is expected to further improve the immunotherapy of advanced HCC.Herein,we compared the different preparation methods for icaritin,interpreted the HCC immune microenvironment and the mechanisms underlying icaritin for treatment of advanced HCC,and discussed both the design of icaritin-based nanomedicines with high icaritin loading and the latest progress in icaritinbased nanomedicines for advanced HCC immunotherapy.Finally,the prospects to promote further clinical translation of icaritin-based nanomedicines for the immunotherapy of advanced HCC were proposed.

关键词： Icaritin Nanomedicine advanced hepatocellular carcinoma Immunotherapy Clinical translation

Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma

在线全文

学校读者我要写书评

暂无评论

World Journal of Hepatology 2022年第8期14卷 1608-1620页

作者： Nika De Wilde Luisa Vonghia Sven Francque Thomas De Somer Ali Bagdadi Eva Staub Jasper Lambrechts Ana-Maria Bucalau Gontran Verset Christophe Van Steenkiste Department of Internal Medicine University Hospital GhentGhent 9000Belgium Department of Gastroenterology and Hepatology University Hospital AntwerpAntwerp 2650Belgium Department of Gastroenterology and Hepatology Maria Middelares HospitalGhent 9000Belgium Department of Psychiatry UniversitéLibre de BruxellesBrussels 1050Belgium Department of Orthopedics University of GhentGhent 9000Belgium Department of Gastroenterology Hepatopancreatology and Digestive OncologyCUB Erasme HospitalUniversitéLibre de BruxellesBrussels 1070Belgium Department of Gastroenterology AZ Maria MiddelaresGhent 9000Belgium Department of Gastroenterology University AntwerpAntwerp 2650Belgium

BACKGROUND hepatocellular carcinoma(HCC)is one of the leading causes of cancer-related death worldwide.The landscape of the systemic treatment for advanced HCC is changing quickly,and recently,the standard of care became either atezolizumab plus bevacizumab or tremelimumab plus durvalumab in the single tremelimumab regular interval durvalumab regimen.Nivolumab monotherapy has proven to be effective sometimes for advanced HCC and could be a valuable treatment option for patients outside current treatment indications and reimbursement criteria for the standard of care.This is a particular population of interest.AIM To evaluate the real-world effectiveness of nivolumab monotherapy in patients with advanced HCC who are not eligible for other treatment.METHODS We conducted a retrospective,multicentric study including 29 patients with advanced HCC from 3 Belgian tertiary hospitals.All patients had had prior chemotherapy or were intolerant or ineligible for treatments.All study subjects received nivolumab 3 mg/kg in monotherapy,administered once every two weeks intravenously.Treatment continued until disease progression,severe adverse events or death.Data were retrieved from patients'medical records.The outcome parameters such as radiological response according to response evaluation criteria in solid tumors(RECIST)criteria,the biological response through the evolution of the alpha-fetoprotein(AFP)level,and clinical response considering both the Child–Pugh(CP)score and the World Health Organization(WHO)performance status(PS)were reported.A safety profile was also reported.Statistical analysis was performed using the SPSS Statistics 27 statistical software package.RESULTS The radiological overall response rate(defined as complete or partial response according to the immune RECIST and modified RECIST criteria)to nivolumab monotherapy was 24.1%.The biological overall response rate(defined as a decrease of≥25%in AFP blood level)was 20.7%.Radiological and biological responses were significantly associated both with each othe

关键词： advanced hepatocellular carcinoma Systemic treatment Immunotherapy Nivolumab Difficult-to-treat patients Real-life setting

Sorafenib in treatment of patients with advanced hepatocellular carcinoma:a systematic review

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2012年第5期11卷 458-466页

作者： Xin Zhang, Xin-Rong Yang, Xiao-Wu Huang, Wei-Min Wang, Ruo-Yu Shi, Yang Xu, Zheng Wang, Shuang-Jian Qiu, Jia Fan ,Jian Zhou Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory for Organ Transplantation, Shanghai 200032, China,Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China Liver Cancer Institute Zhongshan Hospital Fudan University and Shanghai Key Laboratory for Organ Transplantation Shanghai 200032 Shanghai China Institute of Biomedical Sciences Fudan University Shanghai 200032 Shanghai China

BACKGROUND: Sorafenib has become the standard first-line treatment for patients with advanced hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of sorafenib in advanced HCC patients and explore its true value for specific subgroups. DATA SOURCES: A computer-based systematic search from January 2005 to June 2011 with 'sorafenib' and 'advanced hepatocellular carcinoma' as search terms was performed for possible clinical trials. Hazard ratios (HR) and their 95% confidence intervals (CI) for overall survival (OS) and time to progression (TTP), rates of partial response (PR), rates of toxicity effects, and details of subgroup analysis were extracted. Meta-analyses were done using the software Review Manager (version 5.0). RESULTS: Six trials with 1164 patients were included. Based on three randomized controlled trials, the pooled HR (sorafenib/ placebo) was 0.66 for OS (95% CI: 0.56-0.78; Padvanced HCC patients. Meanwhile, sorafenib is less effective for patients with extrahepatic spread, with normal AFP level and with elevated level of bilirubin.

关键词： advanced hepatocellular carcinoma sorafenib systematic review

Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma

在线全文

学校读者我要写书评

暂无评论

Liver Research 2020年第4期4卷 199-205页

作者： Takamasa Ohki Koki Sato Mayuko Kondo Eriko Goto Takahisa Sato Yuji Kondo Masatoshi Akamatsu Shinpei Sato Hideo Yoshida Yukihiro Koike Shuntaro Obi Department of Gastroenterology Mitsui Memorial HospitalTokyoJapan Department of Gastroenterology Kanto Central HospitalTokyoJapan Department of Gastroenterology Teikyo University Medical CenterChiba PrefectureJapan Department of Gastroenterology and Hepatology Kyoundo HospitalTokyoJapan Department of Gastroenterology JR Tokyo General HospitalTokyoJapan Department of Gastroenterology Japanese Red Cross Medical CenterTokyoJapan

Background and aims:Lenvatinib(LEN)is a newly developed tyrosine kinase inhibitor,and is approved as a first-line treatment for advanced hepatocellular carcinoma(HCC)in Japan.This retrospective multi-center study investigated the effect of the relative dose intensity(RDI)of LEN on response rate,progression-free survival(PFS),and overall survival(OS).Methods:This retrospective study enrolled 123 patients with advanced HCC who were treated with LEN at six hospitals in Japan between March 2018 and December 2019.These patients were divided into two groups:RDI≥70%(RDI 70 group,N=70)or RDI<70%(control group,N=53)in the first 30 days.The following data were compared between groups:patient backgrounds,adverse events,treatment out-comes,PFS,and OS.PFS and OS were analyzed using the Kaplan-Meier method,followed by the log-rank test.To identify significant factors that contributed to response,PFS,and OS,multivariate analysis was performed using factors for which P-values were<0.10 in univariate analysis.Results:The proportion of patients with Child-Pugh class 5A was significantly greater in the RDI 70 group than that in the control group(64.3%vs.28.3%,P<0.01).Dose interruption due to adverse events was significantly more common in the control group.The response rate was significantly higher in the RDI 70 group than that in the control group(35.7%vs.11.3%,P<0.01).Median PFS was significantly longer in the RDI 70 group(9.4 vs.4.7 months,P<0.01).Multivariate analysis showed that RDI≥70%(hazard ratio(HR)=0.55,P=0.025),hypertension grade≥2(HR=0.47,P=0.019),and response(HR=0.52,P=0.033)were independently associated with improved PFS.Median OS was also significantly longer in the RDI 70 group(20.0 vs.13.3 months,P=0.045).Multivariate analysis showed that female sex(HR=0.33,P=0.034)and disease control(HR=0.31,P<0.01)were independently associated with improved OS.RDI≥70%was not statistically significant in multivariate analysis.Conclusions:Our study revealed the importance of achieving RDI≥70%in the first 30 days of treatment to max

关键词： advanced hepatocellular carcinoma Lenvatinib(LEN) Relative dose intensity(RDI) Chemotherapy Tyrosine kinase inhibitor

Combination of TACE and FOLFOX4 in the treatment of unresectable advanced hepatocellular carcinoma:a prospective cohort study

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Oncology and Translational Medicine 2020年第5期6卷 208-216页

作者： Jingyan Wang Linzhi Zhang Xiaoming Peng Yun Zhao Lin Zhou Department of Interventional Radiology The Fifth Medical Center of PLA General HospitalBeijing 100039China

Objective The aim of the study was to assess the effectiveness and safety of a combined therapy with transcatheter arterial chemoembolization(TACE)and FOLFOX4,in patients with unresectable advanced hepatocellular carcinoma(HCC).Methods In this study,patients with advanced HCC,that received treatment between November 2015 and October 2017,were recruited.Among these,30 patients were treated with TACE only(TACE group);whereas 33 patients were treated with a combination of FOLFOX4 chemotherapy and TACE(combination group).Survival analyses,including overall survival(OS)and progression free survival(PFS)analysis,were performed for both groups.Following this,the responses of patients to treatment were evaluated every 3 months,and the toxic and adverse events were observed.Results The median follow-up time was 9.2 months(3-36 months).In the combination group,at 3 months,a disease control rate(DCR)of 60.6%,and a median OS of 9.1 months was obtained[95%confidence interval(CI)6.5-11.7].In the TACE group,the DCR and OS were 33.3%and 5.5 months(95%CI 4.3-6.7),respectively.On the other hand,the PFS in the combination and TACE groups were observed as 5.6 months(95%CI 3.6-7.6)and 2.6 months(95%CI 2.0-3.2),respectively.Both these findings indicate a statistically significant difference(P=0.01)between both the groups.Similar TACE associated adverse events were observed in both groups.In the combination group,frequently observed FOLFOX4 related adverse effects included nausea(90.9%),leukopenia(75.8%),thrombocytopenia(69.7%),and vomiting(69.7%).Most adverse reactions were between grades I-III and were alleviated after symptomatic treatments.Conclusion The combination of TACE with FOLFOX4 therapy has better effectivity and safety than TACE alone.

关键词： advanced hepatocellular carcinoma transcatheter arterial chemoembolization(TACE) FOLFOX4

Oncolytic virus-based hepatocellular carcinoma treatment:Current status,intravenous delivery strategies,and emerging combination therapeutic solutions

在线全文

学校读者我要写书评

暂无评论

Asian Journal of Pharmaceutical Sciences 2023年第1期18卷 4-26页

作者： Xinguo Li Xiaonan Sun BingyuanWang Yiling Li Jing Tong The First Hospital of China Medical University Shenyang 110001China The 4th People’s Hospital of Shenyang Shenyang 110031China

Current treatments for advanced hepatocellular carcinoma(HCC)have limited success in improving patients’quality of life and prolonging life expectancy.The clinical need for more efficient and safe therapies has contributed to the exploration of emerging strategies.Recently,there has been increased interest in oncolytic viruses(OVs)as a therapeutic modality for HCC.OVs undergo selective replication in cancerous tissues and kill tumor cells.Strikingly,pexastimogene devacirepvec(Pexa-Vec)was granted an orphan drug status in HCC by the U.S.Food and Drug Administration(FDA)in 2013.Meanwhile,dozens of OVs are being tested in HCC-directed clinical and preclinical trials.In this review,the pathogenesis and current therapies of HCC are outlined.Next,we summarize multiple OVs as single therapeutic agents for the treatment of HCC,which have demonstrated certain efficacy and lowtoxicity.Emerging carrier cell-,bioengineered cell mimetic-or nonbiological vehicle-mediated OV intravenous delivery systems in HCC therapy are described.In addition,we highlight the combination treatments between oncolytic virotherapy and other modalities.Finally,the clinical challenges and prospects of OV-based biotherapy are discussed,with the aim of continuing to develop a fascinating approach in HCC patients.

关键词： Oncolytic viruses(OVs) OV intravenous delivery systems Combination treatments advanced hepatocellular carcinoma (HCC) Pexa-Vec